[1]詹红生, 章振林. 中成药治疗骨质疏松症临床应用指南(2021年)[J]. 中国中西医结合杂志, 2022, 42(4): 393-404.
[2]中华医学会骨质疏松和骨矿盐疾病分会, 章振林. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691.
[3]程鉥泺, 陶雪芬, 赵荣, 等. TLR4/NFκB通路与骨质疏松症关系的研究进展[J]. 中国骨质疏松杂志, 2023, 29(7): 1037-1042.
[4]毛银枫, 崔松香, 华臻, 等. 基于网络药理学探究黄芪白术药对治疗骨质疏松性骨折的作用机制[J]. 江苏大学学报(医学版), 2022, 32(1): 13-17.
[5]Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease[J]. Gastroenterology, 2017, 152(2): 313-321.e2.
[6]余静, 徐钧, 胡华. 克罗恩病患者骨密度、骨代谢以及钙、镁、锌和磷水平特点分析[J]. 中国骨质疏松杂志, 2019, 25(4): 509-511, 522.
[7]冉艳, 米琛, 厉英超. 炎症性肠病患者骨质流失的机制和治疗前景[J]. 胃肠病学, 2021, 26(10): 631-635.
[8]Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology[J]. Stat Med, 2008, 27(8): 1133-1163.
[9]Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations[J]. Nat Genet, 2015, 47(9): 979-986.
[10]ByrskaBishop M, Evani US, Zhao X. Highcoverage wholegenome sequencing of the expanded 1000 Genomes Project cohort including 602 trios[J]. Cell, 2022, 185(18): 3426-3440.e19.
[11]黄国鑫, 陈霞丽, 裴斌. 孟德尔随机化探索骨密度与膝关节骨性关节炎的因果关联[J]. 中国骨质疏松杂志, 2023, 29(4): 512-517.
[12]Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50(5): 693-698.
[13]Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44(2): 512-525.
[14]Lewandowski K, Kaniewska M, Wicek M, et al. Risk factors for osteoporosis among patients with inflammatory bowel disease—do we already know everything?[J]. Nutrients, 2023, 15(5): 1151.
[15]Ratajczak AE, SzymczakTomczak A, Michalak M, et al. Associations between vitamin D, bone mineral density, and the course of inflammatory bowel disease in Polish patients[J]. Pol Arch Intern Med, 2022, 132(12): 16329.
[16]Saadah OI, Annese V, Mosli MH. Prevalence and predictors of reduced bone density in child and adolescent patients with Crohn′s disease[J]. J Clin Densitom, 2021, 24(2): 252-258.
[17]Jin HY, Lim JS, Lee Y, et al. Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease[J]. BMC Pediatr, 2021, 21(1): 35.
[18]Targownik LE, Bernstein CN, Nugent Z, et al. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis[J]. Clin Gastroenterol Hepatol, 2013, 11(3): 278-285.
[19]Hidalgo DF, Boonpheng B, Phemister J, et al. Inflammatory bowel disease and risk of osteoporotic fractures: a metaanalysis[J]. Cureus, 2019, 11(9): e5810.
[20]Bartko J, Reichardt B, Kocijan R, et al. Inflammatory bowel disease: a nationwide study of hip fracture and mortality risk after hip fracture[J]. J Crohns Colitis, 2020, 14: 1256-1263.
[21]Wong SC, CattoSmith AG, Zacharin M. Pathological fractures in paediatric patients with inflammatory bowel disease[J]. Eur J Pediatr, 2014, 173: 141-151.
[22]Felice C, Dal Buono A, Gabbiadini R, et al. Cytokines in spondyloarthritis and inflammatory bowel diseases: from pathogenesis to therapeutic implications[J]. Int J Mol Sci, 2023, 24(4): 3957.
[23]Remily EA, Sax OC, Douglas SJ, et al. Inflammatory bowel disease is associated with increased complications after total knee arthroplasty[J]. Knee, 2023, 40: 313-318.
[24]王世浩, 付赛, 赵宇, 等. 两样本孟德尔随机化研究肾功能对骨质疏松症的因果关系[J]. 现代预防医学, 2022, 49(9): 1537-1542,1589.
[25]Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives[J]. Biomark Res, 2017, 5: 18.
[26]雷鹏蛟, 王亮, 马远征, 等. 微量元素与骨质疏松的相关性研究进展[J]. 中国骨质疏松杂志, 2014, 20(3): 343-346.
[27]Vernia F, Burrelli Scotti G, Bertetti NS, et al. Low vitamin K and vitamin D dietary intake in patients with inflammatory bowel diseases[J]. Nutrients, 2023, 15(7): 1678.
[28]Barbalho SM, Goulart RA, Gasparini RG. Associations between inflammatory bowel diseases and vitamin D[J]. Crit Rev Food Sci Nutr, 2019, 59(8): 1347-1356.
[29]Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2007, 13(4): 416-423.
[30]de Lange KM, Moutsianas L, Lee JC, et al. Genomewide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease[J]. Nat Genet, 2017, 49(2): 256-261.
[31]Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease[J]. Cell, 2016, 167(5): 1415-1429.e19.
[32]Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention[J]. Nat Rev Drug Discov, 2012, 11(3): 234-250.
[33]Guo J, Wang F, Hu Y, et al. Exosomebased bonetargeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases[J]. Cell Rep Med, 2023, 4(1): 100881.
|